Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a milestone in the EXPAND trial with the enrollment of over 1,600 patients.
Noninvasive prenatal testing (NIPT) for fetal aneuploidy screening using cell-free DNA (cfDNA) can incidentally discover maternal cancers, according to a Dutch retrospective study. The analysis ...
Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine Non-invasive prenatal testing, or NIPT, now shapes critical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results